علاج الخط الأول لسرطان الثدي الالتهابي

References

1. The treatment of patients with IBC should involve a combined modality approach comprising preoperative systemic therapy followed by surgery (mastectomy) and radiotherapy.
2. The NCCN Panel recommends preoperative systemic therapy with an anthracycline-based regimen with or without taxanes for the initial treatment of patients with IBC.
3. The NCCN Panel recommends inclusion of trastuzumab in the chemotherapy regimen and is recommended for patients with HER2-positive disease.
4. A pertuzumab-containing regimen may be administered preoperatively to patients with HER2-positive IBC.
5. The accurate assessment of in-breast tumor or regional lymph node response to preoperative systemic therapy is difficult, and should include physical examination and performance of imaging studies (mammogram and/or breast ultrasound and/or breast MRI) that were abnormal at the time of initial tumor staging.